{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:57:09Z","timestamp":1790690229343,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage DLBCL, but there is limited data on the impact of biologic features on outcome. Patients have excellent outcomes, with ~90% survival at 2\u2009years. Over the past several years, sequential prospective trials and large registry studies have evaluated the optimal number of chemotherapy cycles and implemented PET-adapted approaches to reduce the need for radiotherapy. Special consideration must still be given to cases of bulky disease, extranodal disease, fully resected scenarios, and adverse biologic features such as high-grade B-cell lymphoma with double\/triple hit rearrangements. This review presents the evolution of a modern management approach, with a discussion of recent treatment-defining studies.<\/jats:p>","DOI":"10.1038\/s41408-021-00596-z","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T11:02:48Z","timestamp":1645700568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evolution of therapy for limited stage diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Alexandra E.","family":"Rojek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"596_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94:604\u201316.","journal-title":"Am J Hematol"},{"key":"596_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"596_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/bloodadvances.2019000875","volume":"4","author":"P Torka","year":"2020","unstructured":"Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv. 2020;4:253\u201362.","journal-title":"Blood Adv"},{"key":"596_CR4","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001. J Clin Oncol. 2020;38:3003\u201311.","journal-title":"J Clin Oncol"},{"key":"596_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131:174\u201381.","journal-title":"Blood"},{"key":"596_CR6","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","volume":"22","author":"SJ Horning","year":"2004","unstructured":"Horning SJ, Weller E, Kim K, Earle JD, O\u2019Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032\u20138.","journal-title":"J Clin Oncol"},{"key":"596_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N. Engl J Med. 1998;339:21\u201326.","journal-title":"N. Engl J Med"},{"key":"596_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1200\/JCO.2004.05.926","volume":"22","author":"TP Miller","year":"2004","unstructured":"Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004;22:2982\u20134.","journal-title":"J Clin Oncol"},{"key":"596_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.2002.20.1.197","volume":"20","author":"TN Shenkier","year":"2002","unstructured":"Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197\u2013204.","journal-title":"J Clin Oncol"},{"key":"596_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/cncr.11497","volume":"98","author":"MB M\u00f8ller","year":"2003","unstructured":"M\u00f8ller MB, Christensen BE, Pedersen NT. Prognosis of localized diffuse large B-cell lymphoma in younger patients. Cancer. 2003;98:516\u201321.","journal-title":"Cancer"},{"key":"596_CR11","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373\u201380.","journal-title":"J Clin Oncol"},{"key":"596_CR12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"596_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl J Med. 2002;346:235\u201342.","journal-title":"N. Engl J Med"},{"key":"596_CR14","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121\u20137.","journal-title":"J Clin Oncol"},{"key":"596_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"596_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u201391.","journal-title":"Lancet Oncol"},{"key":"596_CR17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16","author":"Y Miao","year":"2019","unstructured":"Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16:634\u201352.","journal-title":"Nat Rev Clin Oncol"},{"key":"596_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"596_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22\u201332.","journal-title":"Blood"},{"key":"596_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood.2018891598","volume":"134","author":"A Goy","year":"2019","unstructured":"Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134:1024\u201336.","journal-title":"Blood"},{"key":"596_CR21","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.1732008100","volume":"100","author":"G Wright","year":"2003","unstructured":"Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"596_CR22","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl J Med. 2008;359:2313\u201323.","journal-title":"N. Engl J Med"},{"key":"596_CR23","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354\u201361.","journal-title":"Blood"},{"key":"596_CR24","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021\u201331. quiz 4250","journal-title":"Blood"},{"key":"596_CR25","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","volume":"121","author":"H Horn","year":"2013","unstructured":"Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253\u201363.","journal-title":"Blood"},{"key":"596_CR26","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460\u20137.","journal-title":"J Clin Oncol"},{"key":"596_CR27","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/bloodadvances.2019000251","volume":"3","author":"A Barraclough","year":"2019","unstructured":"Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, et al. COO and MYC\/BCL2 status do not predict outcome among patients with stage I\/II DLBCL: a retrospective multicenter study. Blood Adv. 2019;3:2013\u201321.","journal-title":"Blood Adv"},{"key":"596_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bjh.13766","volume":"171","author":"A Kumar","year":"2015","unstructured":"Kumar A, Lunning MA, Zhang Z, Migliacci JC, Moskowitz CH, Zelenetz AD. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2015;171:776\u201383.","journal-title":"Br J Haematol"},{"key":"596_CR29","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-Cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33:2848\u201356.","journal-title":"J Clin Oncol"},{"key":"596_CR30","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","volume":"35","author":"DJ Landsburg","year":"2017","unstructured":"Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35:2260\u20137.","journal-title":"J Clin Oncol"},{"key":"596_CR31","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/blood-2017-08-798553","volume":"130","author":"DM Stephens","year":"2017","unstructured":"Stephens DM, Li H, Persky D, Park SI, Bartlett NL, Swinnen LJ, et al. Characteristics and outcomes of patients with double-protein expression in limited stage diffuse large B-Cell lymphoma (DLBCL): analysis of SWOG study S1001 (NCT01359592). Blood. 2017;130:4122\u20134122.","journal-title":"Blood"},{"key":"596_CR32","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.2019000858","volume":"134","author":"Y Wang","year":"2019","unstructured":"Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019;134:1289\u201397.","journal-title":"Blood"},{"key":"596_CR33","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"596_CR34","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1200\/JCO.1989.7.9.1186","volume":"7","author":"SE Jones","year":"1989","unstructured":"Jones SE, Miller TP, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol. 1989;7:1186\u201391.","journal-title":"J Clin Oncol"},{"key":"596_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/sj.bjc.6601675","volume":"90","author":"J Spicer","year":"2004","unstructured":"Spicer J, Smith P, Maclennan K, Hoskin P, Hancock B, Linch D, et al. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin\u2019s lymphoma. Br J Cancer. 2004;90:1151\u20135.","journal-title":"Br J Cancer"},{"key":"596_CR36","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","volume":"34","author":"DM Stephens","year":"2016","unstructured":"Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34:2997\u20133004.","journal-title":"J Clin Oncol"},{"key":"596_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1056\/NEJMoa042040","volume":"352","author":"F Reyes","year":"2005","unstructured":"Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl J Med. 2005;352:1197\u2013205.","journal-title":"N. Engl J Med"},{"key":"596_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","volume":"25","author":"C Bonnet","year":"2007","unstructured":"Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thi\u00e9blemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2007;25:787\u201392.","journal-title":"J Clin Oncol"},{"key":"596_CR39","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","volume":"26","author":"DO Persky","year":"2008","unstructured":"Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258\u201363.","journal-title":"J Clin Oncol"},{"key":"596_CR40","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","volume":"28","author":"J Phan","year":"2010","unstructured":"Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170\u20136.","journal-title":"J Clin Oncol"},{"key":"596_CR41","first-page":"7574","volume":"36","author":"M Pfreundschuh","year":"2018","unstructured":"Pfreundschuh M, Murawski N, Ziepert M, Altmann B, Dreyling MH, Borchmann P, et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA. J Clin Orthod. 2018;36:7574\u20137574.","journal-title":"J Clin Orthod"},{"key":"596_CR42","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","volume":"19","author":"RL Elstrom","year":"2008","unstructured":"Elstrom RL, Leonard JP, Coleman M, Brown RKJ. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol. 2008;19:1770\u20133.","journal-title":"Ann Oncol"},{"key":"596_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/bjc.2013.338","volume":"109","author":"CY Cheah","year":"2013","unstructured":"Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer. 2013;109:312\u20137.","journal-title":"Br J Cancer"},{"key":"596_CR44","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.clml.2017.10.003","volume":"18","author":"MC Cheung","year":"2018","unstructured":"Cheung MC, Mittmann N, Earle CC, Rahman F, Liu N, Singh S. Are we choosing wisely in lymphoma? Excessive use of surveillance CT imaging in patients with diffuse large B-cell Lymphoma (DLBCL) in long-term remission. Clin Lymphoma Myeloma Leuk. 2018;18:e27\u201334.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"596_CR45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/annonc\/mdr189","volume":"22","author":"LH Sehn","year":"2011","unstructured":"Sehn LH, Savage KJ, Hoskins P, Klasa R, Shenkier T, Gascoyne RD, et al. Treatment of limited-stage DLBCL can be effectively tailored using a PET-based approach. Annals of Oncology. 2011;22:90\u20131.","journal-title":"Annals of Oncology"},{"key":"596_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/PPO.0b013e31826c5907","volume":"18","author":"LH Sehn","year":"2012","unstructured":"Sehn LH. Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J. 2012;18:421\u20136.","journal-title":"Cancer J"},{"key":"596_CR47","doi-asserted-by":"publisher","unstructured":"S Bologna, T Vander Borght, J Briere, V Ribrag, GL Damaj, C Thieblemont, et al. Bastie. Early Positron Emission Tomography Response\u2010Adapted Treatment in Localized Diffuse Large B\u2010Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH 09\u20101B Trial. Hematol Oncol. 2021. https:\/\/doi.org\/10.1002\/hon.5_2879.","DOI":"10.1002\/hon.5_2879"},{"key":"596_CR48","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"596_CR49","doi-asserted-by":"publisher","unstructured":"Zhao P, Yu T, Pan Z. Prognostic value of the baseline 18F-FDG PET\/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med. 2020. https:\/\/doi.org\/10.1007\/s12149-020-01531-1.","DOI":"10.1007\/s12149-020-01531-1"},{"key":"596_CR50","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2020","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2020;394:2271\u201381.","journal-title":"Lancet"},{"key":"596_CR51","first-page":"7507","volume":"37","author":"EJ Lugtenburg","year":"2019","unstructured":"Lugtenburg EJ, Brown P, van der Holt B, D\u2019Amore F, Koene HR, de Jongh E, et al. Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: results from a randomized HOVON-Nordic Lymphoma Group phase III study. J Clin Orthod. 2019;37:7507\u20137507.","journal-title":"J Clin Orthod"},{"key":"596_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hon.2561","volume":"37","author":"A Rozental","year":"2019","unstructured":"Rozental A, Gafter-Gvili A, Vidal L, Raanani P, Gurion R. The role of maintenance therapy in patients with diffuse large B cell lymphoma: a systematic review and meta-analysis. Hematol Oncol. 2019;37:27\u201334.","journal-title":"Hematol Oncol"},{"key":"596_CR53","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/cam4.2798","volume":"9","author":"S Tokola","year":"2020","unstructured":"Tokola S, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O. Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients. Cancer Med. 2020;9:1966\u201377.","journal-title":"Cancer Med"},{"key":"596_CR54","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/10428194.2018.1506586","volume":"60","author":"GD Grass","year":"2019","unstructured":"Grass GD, Mills MN, Ahmed KA, Liveringhouse CL, Montejo ME, Robinson TJ, et al. Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. Leuk Lymphoma. 2019;60:886\u201393.","journal-title":"Leuk Lymphoma"},{"key":"596_CR55","doi-asserted-by":"publisher","unstructured":"Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B cell lymphoma in the rituximab-era. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2020005112","DOI":"10.1182\/blood.2020005112"},{"key":"596_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","volume":"124","author":"MB M\u00f8ller","year":"2004","unstructured":"M\u00f8ller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation\u2014a population-based study of 1575 cases. Br J Haematol. 2004;124:151\u20139.","journal-title":"Br J Haematol"},{"key":"596_CR57","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1182\/blood-2021-147938","volume":"138","author":"DM Stephens","year":"2021","unstructured":"Stephens DM, Li H, Constine LS, Leonard JP, Kahl BS, Song JY, et al. Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592). Blood. 2021;138:1423.","journal-title":"Blood"},{"key":"596_CR58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/hon.2487","volume":"36","author":"M Nijland","year":"2018","unstructured":"Nijland M, Boslooper K, van Imhoff G, Kibbelaar R, Joosten P, Storm H, et al. Relapse in stage I(E) diffuse large B-cell lymphoma. Hematol Oncol. 2018;36:416\u201321.","journal-title":"Hematol Oncol"},{"key":"596_CR59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.14392","volume":"176","author":"R Kridel","year":"2017","unstructured":"Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176:210\u201321.","journal-title":"Br J Haematol"},{"key":"596_CR60","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","volume":"29","author":"U Vitolo","year":"2011","unstructured":"Vitolo U, Chiappella A, Ferreri AJM, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766\u201372.","journal-title":"J Clin Oncol"},{"key":"596_CR61","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1001\/jama.2012.91077","volume":"308","author":"J Munoz","year":"2012","unstructured":"Munoz J, Kuriakose P. Antibiotic-refractory sinusitis. JAMA. 2012;308:2399\u20132400.","journal-title":"JAMA"},{"key":"596_CR62","doi-asserted-by":"publisher","unstructured":"Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek M-K, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2021012888.","DOI":"10.1182\/blood.2021012888"},{"key":"596_CR63","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin\u2019s lymphoma: a risk model. Ann Oncol. 2002;13:1099\u2013107.","journal-title":"Ann Oncol"},{"key":"596_CR64","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","volume":"90","author":"WM Tai","year":"2011","unstructured":"Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90:809\u201318.","journal-title":"Ann Hematol"},{"key":"596_CR65","doi-asserted-by":"publisher","first-page":"8386","DOI":"10.1002\/cam4.3448","volume":"9","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, M\u00fcller SP, Farsijani N, Hertenstein B, Franzius C, et al. Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. Cancer Med. 2020;9:8386\u201396.","journal-title":"Cancer Med"},{"key":"596_CR66","doi-asserted-by":"publisher","first-page":"13367","DOI":"10.18632\/oncotarget.14531","volume":"8","author":"DH Yoon","year":"2017","unstructured":"Yoon DH, Sohn BS, Oh SY, Lee W-S, Lee SM, Yang D-H, et al. Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget. 2017;8:13367\u201374.","journal-title":"Oncotarget"},{"key":"596_CR67","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s00277-020-04284-z","volume":"99","author":"S Kang","year":"2020","unstructured":"Kang S, Cho H, Sohn BS, Oh SY, Lee W-S, Lee SM, et al. Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). Ann Hematol. 2020;99:2831\u20136.","journal-title":"Ann Hematol"},{"key":"596_CR68","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III Trial. J Clin Oncol. 2018;36:2024\u201334.","journal-title":"J Clin Oncol"},{"key":"596_CR69","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2010-06-288480","volume":"117","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011;117:1958\u201365.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00596-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:03:02Z","timestamp":1669233782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00596-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00596-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.E.R. has no competing interests to report. S.M.S. has no competing interests related to this work. There was no funding from any sources for this work. Per ICJME guidelines, S.M.S. has served as a consultant for ADC Therapeutics, Gilead, BMS, Morphosys, Janssen, Karyopharm, Genentech, TGTX, Celgene, Bayer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}